CareASSIST is here to help you get the information and support you need. In addition to the program offerings, you may also find the following downloads and online resources helpful.
The CareASSIST application covers all aspects of the program: Access and Reimbursement, Financial Assistance, and Resource Support. Follow the directions on the form to apply, or call 1-833-WE+CARE to get started.
The CareASSIST brochure contains an overview of the program and its offerings.
The CareASSIST Copay Program overview brochure describes the program and its requirements.
An overview of potential sources of prescription assistance.
Certain patients may require information or assistance beyond what CareASSIST may offer. Below are links to external organizations that may be able to help, or you can call 1-833-WE+CARE to learn about alternate coverage options.
Learn about Medicaid in your state and if you may be eligible.
Learn about Medicare and prescription drug coverage, eligibility, and how to access the care you may need.
Find help for insurance and healthcare access problems.
Offers help and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments.
A nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.
A global network offering quality cancer support to millions of people touched by cancer, available online and at community-based centers and hospitals.
A not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.
A leading national organization dedicated to providing free support services and financial assistance to anyone affected by cancer.
ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS